The Obesity ETF (SLIM)
NASDAQ (NMS) Summary
SLIM Chart
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.
The Obesity ETF (SLIM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has The Obesity ETF ever had a stock split?
The Obesity ETF Profile
| NASDAQ (NMS) Exchange | United States Country |
Overview
The investment fund is designed to provide investors with exposure to companies worldwide that play a significant role in addressing obesity and related health conditions. By tracking the Solactive Obesity Index, the fund aims to mirror the performance of businesses engaged in offering solutions to obesity problems, including those in biotechnology, pharmaceuticals, healthcare, and medical devices specifically focusing on obesity and associated diseases. Additionally, companies involved in weight loss programs, dietary supplements, or the provision of plus-sized apparel are included. The fund commits a minimum of 80% of its net assets to stocks included in the Solactive Obesity Index and is classified as non-diversified, meaning it may invest more heavily in fewer sectors or companies.
Products and Services
- Biotechnology and Pharmaceutical Companies
- Healthcare and Medical Device Companies
- Weight Loss Programs and Supplements
- Plus-Sized Apparel
Investment in biotech and pharmaceutical companies that are at the forefront of developing treatments and medications for obesity and obesity-related conditions. These companies are engaged in groundbreaking research and the development of drugs that could potentially mitigate the effects of obesity on the human body or aid in weight management.
Funding is allocated to healthcare providers and manufacturers of medical devices designed to treat obesity and its complications. This includes surgical and non-surgical weight loss treatments, as well as devices that help monitor and manage patient health related to obesity.
Investment extends to companies providing structured weight loss programs and dietary supplements aimed at helping individuals lose weight. These programs often offer a combination of nutritional guidance, behavioral counseling, and physical activity routines to promote weight loss and healthy living.
The fund also invests in companies that specialize in plus-sized apparel, recognizing the importance of catering to a market segment that demands fashion and comfort regardless of body size. This investment not only acknowledges the growing market demand but also supports inclusivity and the well-being of individuals with obesity.
Contact Information
